Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 8 |
List of Tables | 8 | 1 |
List of Figures | 9 | 1 |
Introduction | 10 | 1 |
Global Markets Direct Report Coverage | 10 | 1 |
Thrombocytopenia Overview | 11 | 1 |
Therapeutics Development | 12 | 2 |
Pipeline Products for Thrombocytopenia Overview | 12 | 1 |
Pipeline Products for Thrombocytopenia Comparative Analysis | 13 | 1 |
Thrombocytopenia Therapeutics under Development by Companies | 14 | 2 |
Thrombocytopenia Therapeutics under Investigation by Universities/Institutes | 16 | 1 |
Thrombocytopenia Pipeline Products Glance | 17 | 3 |
Late Stage Products | 17 | 1 |
Clinical Stage Products | 18 | 1 |
Early Stage Products | 19 | 1 |
Thrombocytopenia Products under Development by Companies | 20 | 3 |
Thrombocytopenia Products under Investigation by Universities/Institutes | 23 | 1 |
Thrombocytopenia Companies Involved in Therapeutics Development | 24 | 31 |
3SBio Inc. | 24 | 1 |
AkaRx Inc | 25 | 1 |
Amarillo Biosciences, Inc. | 26 | 1 |
Amgen Inc. | 27 | 1 |
arGEN-X BV | 28 | 1 |
BioLineRx, Ltd. | 29 | 1 |
Biotest AG | 30 | 1 |
Boehringer Ingelheim GmbH | 31 | 1 |
Bolder Biotechnology, Inc. | 32 | 1 |
Bristol-Myers Squibb Company | 33 | 1 |
Cellerant Therapeutics, Inc. | 34 | 1 |
Genosco | 35 | 1 |
Hansa Medical AB | 36 | 1 |
Immunomedics, Inc. | 37 | 1 |
Intas Pharmaceuticals Ltd. | 38 | 1 |
Jiangsu Hengrui Medicine Co., Ltd. | 39 | 1 |
Merck &Co., Inc. | 40 | 1 |
Momenta Pharmaceuticals, Inc. | 41 | 1 |
Myelo Therapeutics GmbH | 42 | 1 |
Neumedicines Inc. | 43 | 1 |
Novartis AG | 44 | 1 |
Pfizer Inc. | 45 | 1 |
PhytoHealth Corporation | 46 | 1 |
Prophylix Pharma AS | 47 | 1 |
Protalex, Inc. | 48 | 1 |
Rigel Pharmaceuticals, Inc. | 49 | 1 |
Shionogi &Co., Ltd. | 50 | 1 |
Shire Plc | 51 | 1 |
STATegics, Inc. | 52 | 1 |
UCB SA | 53 | 1 |
ViroMed Co Ltd | 54 | 1 |
Thrombocytopenia Therapeutics Assessment | 55 | 9 |
Assessment by Monotherapy Products | 55 | 1 |
Assessment by Target | 56 | 2 |
Assessment by Mechanism of Action | 58 | 2 |
Assessment by Route of Administration | 60 | 2 |
Assessment by Molecule Type | 62 | 2 |
Drug Profiles | 64 | 81 |
Antibody for Autoimmune Disorders and Inflammation Drug Profile | 64 | 1 |
ARGX-113 Drug Profile | 65 | 2 |
avatrombopag Drug Profile | 67 | 2 |
BBT-059 Drug Profile | 69 | 1 |
BI-655064 Drug Profile | 70 | 2 |
BL-8040 Drug Profile | 72 | 11 |
BMS-986004 Drug Profile | 83 | 1 |
BT-595 Drug Profile | 84 | 1 |
CLT-009 Drug Profile | 85 | 1 |
eltrombopag olamine Drug Profile | 86 | 6 |
eltrombopag olamine Drug Profile | 92 | 1 |
fostamatinib disodium Drug Profile | 93 | 6 |
GL-2045 Drug Profile | 99 | 1 |
GSK-2285921 Drug Profile | 100 | 2 |
Hetrombopag Olamine Drug Profile | 102 | 1 |
interferon alfa Drug Profile | 103 | 2 |
lusutrombopag Drug Profile | 105 | 1 |
M-281 Drug Profile | 106 | 1 |
MK-8723 Drug Profile | 107 | 1 |
Monoclonal Antibody to Agonize Thrombopoietin Receptor for Thrombocytopenia Drug Profile | 108 | 1 |
Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders Drug Profile | 109 | 1 |
Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders Drug Profile | 110 | 1 |
Myelo-001 Drug Profile | 111 | 1 |
NMIL-121 Drug Profile | 112 | 3 |
Oligonucleotides to Activate miRNA-150 for Thrombocytopenia and Anemia Drug Profile | 115 | 1 |
PEG-VM501 Drug Profile | 116 | 1 |
PHN-013 Drug Profile | 117 | 1 |
PRTX-100 Drug Profile | 118 | 7 |
Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases Drug Profile | 125 | 1 |
romiplostim Drug Profile | 126 | 3 |
romiplostim biosimilar Drug Profile | 129 | 1 |
SHP-652 Drug Profile | 130 | 3 |
SKIO-703 Drug Profile | 133 | 1 |
Small Molecules to Inhibit BLVRB for Thrombocytopenia Drug Profile | 134 | 1 |
Small Molecules to Inhibit PF4 for Heparin Induced Thrombocytopenia Drug Profile | 135 | 1 |
STST-4 Drug Profile | 136 | 1 |
thrombopoietin Drug Profile | 137 | 1 |
Tromplate Drug Profile | 138 | 1 |
TXA-302 Drug Profile | 139 | 1 |
UCB-7665 Drug Profile | 140 | 1 |
veltuzumab Drug Profile | 141 | 4 |
Thrombocytopenia Dormant Projects | 145 | 3 |
Thrombocytopenia Discontinued Products | 148 | 1 |
Thrombocytopenia Product Development Milestones | 149 | 13 |
Featured News &Press Releases | 149 | 1 |
Oct 20, 2016: Rigel Announces Results from the Second FIT Phase 3 Study and the Long-Term Open-Label Extension Study for Fostamatinib in ITP | 149 | 1 |
Oct 06, 2016: Amarillo Biosciences Receives Approval of Patent Claims - Treatment of Thrombocytopenia Using Orally Administered Interferon | 150 | 1 |
Sep 22, 2016: argenx provides update on lead program ARGX-113 at R&D day in New York | 151 | 1 |
Sep 15, 2016: Rigel Restructures to Focus on Fostamatinib Commercialization | 151 | 1 |
Aug 30, 2016: Rigel Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP | 152 | 1 |
Aug 25, 2016: Health Canada issues advisory on REVOLADE citing risk of severe hepatotoxicity | 153 | 1 |
Jun 10, 2016: Novartis highlights long-term safety data of Revolade in adults with chronic immune thrombocytopenia, a rare blood disorder | 154 | 1 |
May 19, 2016: Amgen Highlights Data on Nplate (romiplostim) at 21st Congress Of The European Hematology Association | 155 | 1 |
Apr 19, 2016: Nplate (Romiplostim) Study In The Lancet Shows Significant Increase In Durable Platelet Response Among Children With Immune Thrombocytopenia | 156 | 1 |
Apr 07, 2016: Novartis receives EU approval for Revolade as first-in-class therapy for children aged 1 year and above with chronic ITP | 157 | 1 |
Apr 01, 2016: Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP | 158 | 1 |
Jan 29, 2016: CHMP adopts extension to existing therapeutic indication for eltrombopag | 159 | 1 |
Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP | 159 | 1 |
Jan 07, 2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco | 160 | 1 |
Dec 01, 2015: Shionogi Launches MULPLETA Tablets 3mg In Japan for Improvement of Thrombocytopenia | 161 | 1 |
Appendix | 162 | 2 |
Methodology | 162 | 1 |
Coverage | 162 | 1 |
Secondary Research | 162 | 1 |
Primary Research | 162 | 1 |
Expert Panel Validation | 162 | 1 |
Contact Us | 162 | 1 |
Disclaimer | 163 | 1 |